JGC
NBIX icon

J. Goldman & Co’s Neurocrine Biosciences NBIX Stock Holding History

J. Goldman & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,800
Closed -$1.99M – 558
2025
Q2 		$1.99M Sell
15,800
-34,200
-68% -$3.92M 0.05% 276
2025
Q1 		$5.53M Buy
50,000
+5,500
+12% +$697K 0.14% 196
2024
Q4 		$6.07M Buy
+44,500
New +$5.5M 0.16% 182
2024
Q1 		– Sell
-38,900
Closed -$5.13M – 484
2023
Q4 		$5.13M Buy
38,900
+22,100
+132% +$2.54M 0.21% 123
2023
Q3 		$1.89M Buy
+16,800
New +$1.77M 0.07% 206

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

J. Goldman & Co's NBIX Position: Q1 2026 in Review

J. Goldman & Co sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 53,303 shares — an estimated $7.56M sold.

J. Goldman & Co first reported a position in NBIX in Q1 2017 and held it in 13 quarters. The position peaked at $10.8M in Q1 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • J. Goldman & Co reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 53,303 Neurocrine Biosciences shares in Q1 2026, an estimated $7.56M.
  • J. Goldman & Co first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 13 quarters.
  • J. Goldman & Co's Neurocrine Biosciences position peaked at $10.8M in Q1 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.